Exact Sciences Corp.

History

Year	Detail
1995	Stanley Lapidus and Anthony Shuber founded Exact Sciences Corp in Marlborough, Massachusetts, U.S..
2001	Exact Sciences Corp. went public through an Initial Public Offering (IPO) on NASDAQ.
2012	Exact Sciences Corp. has completed patient enrollment in its DeeP-C pivotal trial for the colorectal cancer screening study.
2014	Exact Sciences Corp. and Cologuard had received a memorandum from the Centers for Medicare and Medicaid Services (CMS).
	The American Cancer Society (ACS) included Cologuard in its colorectal cancer screening guidelines.
2017	Exact Sciences Corp. acquired Sampleminded, a healthcare information technology company, to bolster IT capabilities.
2018	Exact Sciences Corp. acquired Biomatrica, one of the leading providers of DNA preservation technology. Under this acquisition, the company aims to utilize Biomatrica's proprietary technology to support the ongoing and future development of its blood-based cancer detection tests.
2019	Exact Sciences Corp. initiated a BLUE-C prospective study to support FDA approval for an advanced Cologuard and a colon cancer blood test.
2020	Exact Sciences Corp. acquired Paradigm and Viomics to offer a differentiated late-stage therapy selection test, deep sequencing, and biomarker discovery capabilities.
2021	Exact Sciences Corp. has acquired Thrive Earlier Detection to lead cancer diagnostics and transform patients' future through earlier detection and treatment guidance.
	Exact Sciences Corp. acquired Ashion Analytics and entered into a research collaboration with the City of Hope's Genomics Institute, Tagen.
	Exact Sciences Corp. collaborated with Jefferson Health for the Multi-cancer Earlier Detection (MCED) test.
2022	Exact Sciences Corp. acquired Prevention Genetics to expand hereditary cancer testing (HCT) usage.
2023	Exact Sciences Corp. launched the OncoExTra cancer therapy selection test in the U.S. This test will offer reliable and actionable results personalized to each patient.